Giordani, Elena
Allegretti, Matteo
Sinibaldi, Alberto
Michelotti, Francesco
Ferretti, Gianluigi
Ricciardi, Elena
Ziccheddu, Giovanna
Valenti, Fabio
Di Martino, Simona
Ercolani, Cristiana
Giannarelli, Diana
Arpino, Grazia
Gori, Stefania
Omarini, Claudia
Zambelli, Alberto
Bria, Emilio
Paris, Ida
Buglioni, Simonetta
Giacomini, Patrizio http://orcid.org/0000-0001-6109-1709
Fabi, Alessandra
Funding for this research was provided by:
Lazio Innova (A0375-2020-36630)
Roche Pharmaceuticals
Article History
Received: 12 February 2024
Accepted: 20 June 2024
First Online: 29 June 2024
Declarations
:
: Informed consents and study protocol were approved by the Regina Elena Ethical Review Board for T-DM1-treated patients (LiqBreasTrack, RS-857/16; LiqERBcept/GIM21, RS-1070/18), and patients with other tumors or healthy blood donors (CEC/707/15).
: Not applicable.
: The authors declare no competing interests. The study was unconditionally supported by Roche Pharmaceutical (AF).